Rationale and design of the RIACT-study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial

Lena Schiffer, Mario Schiffer, Saskia Merkel, Anke Schwarz, Michael Mengel, Christopher Jürgens, Christoph Schroeder, Alexander A Zoerner, Kerstin Püllmann, Verena Bröcker, Jan U Becker, Maximilian E Dämmrich, Jana Träder, Anika Grosshennig, Frank Biertz, Hermann Haller, Armin Koch, Wilfried Gwinner, Lena Schiffer, Mario Schiffer, Saskia Merkel, Anke Schwarz, Michael Mengel, Christopher Jürgens, Christoph Schroeder, Alexander A Zoerner, Kerstin Püllmann, Verena Bröcker, Jan U Becker, Maximilian E Dämmrich, Jana Träder, Anika Grosshennig, Frank Biertz, Hermann Haller, Armin Koch, Wilfried Gwinner

Abstract

Background: Acute kidney allograft rejection is a major cause for declining graft function and has a negative impact on the long-term graft survival. The majority (90%) of acute rejections are T-cell mediated and, therefore, the anti-rejection therapy targets T-cell-mediated mechanisms of the rejection process. However, there is increasing evidence that intragraft B-cells are also important in the T-cell-mediated rejections. First, a significant proportion of patients with acute T-cell-mediated rejection have B-cells present in the infiltrates. Second, the outcome of these patients is inferior, which has been related to an inferior response to the conventional anti-rejection therapy. Third, treatment of these patients with an anti-CD20 antibody (rituximab) improves the allograft outcome as reported in single case observations and in one small study. Despite the promise of these observations, solid evidence is required before incorporating this treatment option into a general treatment recommendation.

Methods/design: The RIACT study is designed as a randomized, double-blind, placebo-controlled, parallel group multicenter Phase III study. The study examines whether rituximab, in addition to the standard treatment with steroid-boli, leads to an improved one-year kidney allograft function, compared to the standard treatment alone in patients with acute T-cell mediated tubulointerstitial rejection and significant B-cell infiltrates in their biopsies. A total of 180 patients will be recruited.

Discussion: It is important to clarify the relevance of anti-B cell targeting in T-cell mediated rejection and answer the question whether this novel concept should be incorporated in the conventional anti-rejection therapy.

Trial registration: Clinical trials gov. number: NCT01117662.

Figures

Figure 1
Figure 1
Flowchart of the study design of the RIACT study. Independent from the study protocol, all patients will receive steroid boli for rejection therapy.

References

    1. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–S155.
    1. Webster A, Pankhurst T, Rinaldi F, Chapman JR, Craig JC. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. Cochrane Database Syst Rev. 2006;2:CD004756.
    1. Massy ZA, Guijarro C, Kasiske BL. Clinical predictors of chronic renal allograft rejection. Kidney Int Suppl. 1995;52:S85–S88.
    1. Nickerson P, Jeffery J, Gough J, McKenna R, Grimm P, Cheang M, Rush D. Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant. J Am Soc Nephrol. 1998;9:482–487.
    1. Seron D, Moreso F, Fulladosa X, Hueso M, Carrera M, Grinyo JM. Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney Int. 2002;61:727–733. doi: 10.1046/j.1523-1755.2002.00174.x.
    1. Rush D, Nickerson P, Gough J, McKenna R, Grimm P, Cheang M, Trpkov K, Solez K, Jeffery J. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol. 1998;9:2129–2134.
    1. Schwarz A, Mengel M, Gwinner W, Radermacher J, Hiss M, Kreipe H, Haller H. Risk factors for chronic allograft nephropathy after renal transplantation: a protocol biopsy study. Kidney Int. 2005;67:341–348. doi: 10.1111/j.1523-1755.2005.00087.x.
    1. Mengel M, Gwinner W, Schwarz A, Bajeski R, Franz I, Bröcker V, Becker T, Neipp M, Klempnauer J, Haller H, Kreipe H. Infiltrates in protocol biopsies from renal allografts. Am J Transplant. 2007;7:356–365. doi: 10.1111/j.1600-6143.2006.01635.x.
    1. Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M, Salvatierra O Jr. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med. 2003;349:125–138. doi: 10.1056/NEJMoa035588.
    1. Hippen BE, DeMattos A, Cook WJ, Kew CE, Gaston RS. Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant. 2005;5:2248–2252. doi: 10.1111/j.1600-6143.2005.01009.x.
    1. Tsai EW, Rianthavorn P, Gjertson DW, Wallace WD, Reed EF, Ettenger RB. CD20+ lymphocytes in renal allografts are associated with poor graft survival in pediatric patients. Transplantation. 2006;82:1769–1773. doi: 10.1097/01.tp.0000250572.46679.45.
    1. Dorner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol. 2009;5:433–441. doi: 10.1038/nrrheum.2009.141.
    1. Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant. 2008;8:2607–2617. doi: 10.1111/j.1600-6143.2008.02411.x.
    1. Lehnhardt A, Mengel M, Pape L, Ehrich JH, Offner G, Strehlau J. Nodular B-cell aggregates associated with treatment refractory renal transplant rejection resolved by rituximab. Am J Transplant. 2006;6:847–851. doi: 10.1111/j.1600-6143.2006.01246.x.
    1. Alausa M, Almagro U, Siddiqi N, Zuiderweg R, Medipalli R, Hariharan S. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab. Clin Transplant. 2005;19:137–140. doi: 10.1111/j.1399-0012.2004.00292.x.
    1. Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol. 2006;24:467–496. doi: 10.1146/annurev.immunol.24.021605.090517.
    1. Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G. Pharmacodynamics of rituximab in kidney transplantation. Transplantation. 2007;84:S33–S36. doi: 10.1097/01.tp.0000296122.19026.0f.
    1. Zand MS. Rituximab in pediatric renal transplantation: a treatment for allograft rejection with B-cell infiltrates? Am J Transplant. 2008;8:2489–2490. doi: 10.1111/j.1600-6143.2008.02454.x.
    1. Steinmetz OM, Lange-Husken F, Turner JE, Vernauer A, Helmchen U, Stahl RA, Thaiss F, Panzer U. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. Transplantation. 2007;84:842–850. doi: 10.1097/01.tp.0000282786.58754.2b.
    1. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol. 2005;16:763–773. doi: 10.1681/ASN.2004070549.
    1. Fleming TR, Harrington DP, O’Brien PC. Designs for group sequential tests. Control Clin Trials. 1984;5:348–361. doi: 10.1016/S0197-2456(84)80014-8.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera